Adrixetinib is under clinical development by Qurient and currently in Phase I for Hematological Tumor. According to GlobalData, Phase I drugs for Hematological Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Adrixetinib LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Adrixetinib overview

Adrixetinib (Q-702) is under development for the treatment of advanced solid tumors including esophageal cancer, gastric cancer, cervical cancer, hepatocellular carcinoma, gastroesophageal (GE) junction carcinomas, metastatic hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), relapsed and refractory acute myeloid leukemia, myelodysplastic syndrome and hematologic malignancies. It is administered through oral route. The drug candidate acts by targeting Axl, Mer and CSF1 receptor tyrosine kinases.

Qurient overview

Qurient is a biotechnology company. It develops drugs for unmet medical needs of atopic diseases and cancer. The company offers pipeline products that include Q301, a topical leukotriene inhibitor for the treatment of atopic dermatitis; Telacebec (Q203), a Cyt bc1 Inhibitor for combating mycobacterium associated tuberculosis infection; and Q702, an Axl/Mer/CSF1R triple kinase inhibitor for the treatment of drug resistant non-small cell lung cancer and other cancer types. Qurient in-licensed Q702 from Max Planck Innovation and Lead Discovery Center. The company is also advancing its pre-clinical pipeline that includes a topical 5-lipoxygenase inhibitor to treat allergic and atopic diseases; and selective CDK7 inhibitors to treat cancer. Qurient is headquartered in Seongnam, Gyeonggi, South Korea.

For a complete picture of Adrixetinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.